Hepatitis C virus infection in children in the era of direct-acting antiviral

Pawłowska, Małgorzata; Sobolewska-Pilarczyk, Małgorzata; Domagalski, Krzysztof

doi:10.3748/wjg.v24.i24.2555

Cited by 18 publications

(13 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with direct‐acting antivirals (DAAs) in children aged ≥5 years has been reported on . In this study, ledipasvir‐sofosbuvir for 12 weeks was highly effective in treating children 3 to <6 years old with CHC infection, with 97% of participants reaching SVR12 and none experiencing VF.…”

Section: Discussionmentioning

confidence: 83%

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

et al. 2019

View full text Add to dashboard Cite

For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir‐sofosbuvir in HCV‐infected children aged 3 to <6 years. In an open‐label study, patients 3 to <6 years old chronically infected with HCV genotype 1 (n = 33) or 4 (n = 1) received weight‐based doses of combined ledipasvir‐sofosbuvir as granules (33.75 mg/150 mg for weights <17 kg or 45 mg/200 mg for weights ≥17 kg) for 12 weeks. The primary endpoint was sustained virological response 12 weeks after treatment (SVR12). For the first 14 patients, intensive pharmacokinetic sampling was done on day 10 of treatment. All patients had been infected through perinatal transmission and were treatment naïve. No patients had known cirrhosis. Ten patients (29%) weighed <17 kg. SVR12 was achieved in 97% of patients (33 of 34); the patient who did not achieve SVR12 was 3 years old and discontinued treatment after 5 days because of an adverse event “abnormal drug taste.” The most common adverse events were vomiting (24% of patients), cough (21%), and pyrexia (21%). No patients experienced a serious adverse event. Intensive pharmacokinetic analysis of 13 patients for whom data were evaluable confirmed that the doses selected were appropriate. Conclusion: Ledipasvir‐sofosbuvir was well tolerated and highly effective in children 3 to <6 years old with chronic HCV infection.

show abstract

Section: Discussionmentioning

confidence: 83%

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The global prevalence of HCV has been estimated at 1%, which equates to approximately 71 million people [20]. Chronic hepatitis C virus infection varies between 0.6% and 10% depending on geographical location [21]. In Western Europe, the estimated prevalence of hepatitis C is 1.5%-3.5% [22].…”

Section: Discussionmentioning

confidence: 99%

Burden of viral hepatitis caused by specific aetiologies in China, 1990-2016: findings from the GBD 2016

Wang

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose The aim of this study is to quantify the burden caused by viral hepatitis in China from 1990 to 2016. Methods: Data from the GBD 2016 study were extracted to calculate incidence, prevalence and disability-adjusted life years (DALYs). Trends in DALYs were assessed in 33 provinces/regions. Results: From 1990 to 2016, the total incidence of hepatitis decreased by 88.5%. However, the prevalence of hepatitis (counts in thousands), increased by 37.6% from 153,856 (95% UI: 136,047-172,319) in 1990 to 211,721 (95% UI: 179,776-240,981) in 2016, with age-standardized prevalence rates changing slightly. The number and age-standardized rates of prevalence increased by 35.9% and 1.6% for hepatitis B, respectively, and by 81.8% and 30.4% for hepatitis C. Guangxi, Guangdong and Hainan had the highest age-standardized prevalence rates (≥16,500 per 100,000). Tibet, Qinghai and Gansu had the highest age-standardized DALYs rates (≥40 per 100,000). The largest absolute number of DALYs was observed in the 15-49 year age group in 2016. The highest rate of DALYs occurred in males aged 50-69 years and in females aged ≧70 years. Conclusion: The incidence and DALYs of viral hepatitis decreased dramatically from 1990 to 2016. However, the prevalence still remains at a high level, which may result in heavy burdens in the future.

show abstract

“…Since 2015, the development and approval of novel, oral, interferon-free, antiviral treatment with direct-acting antivirals (DAAs) has substantially improved the treatment of HCV infection[ 18 , 19 ]. With an efficacy approaching 100% and a short duration of therapy, DAAs are a highly effective, safe, and well-tolerated alternative for previously used therapies based on interferons[ 18 , 19 ]. Currently, approximately 10 different DAA combinations have been approved for use in adults, increasing the prospect of HCV elimination on a population level[ 1 , 18 ].…”

Section: Management Of Hcv Infection In Children and Adolescentsmentioning

confidence: 99%

Management of hepatitis C in children and adolescents during COVID-19 pandemic

Pokorska‐Śpiewak

Śpiewak

2020

WJH

View full text Add to dashboard Cite

In recent years, significant progress in the antiviral treatment of chronic hepatitis C (CHC) has been made due to the development of interferon-free therapies. Three different highly effective, oral direct-acting antiviral (DAA) regimens have been approved for use in adolescents with CHC between the ages of 12-years-old and 17-years-old in Europe. According to the current recommendations, all treatment-naïve and treatment-experienced children with CHC virus infection should be considered for DAA therapy to prevent the possible progression of hepatitis C virus-related liver disease and its complications. However, the novel coronavirus disease 2019 outbreak, which was classified as a pandemic in March 2020, is currently spreading throughout the world, resulting in a disruption of the healthcare system. This disruption is having a negative impact on the care of patients with chronic diseases, including children with CHC. Thus, several efforts have to be made by pediatric hepatologists to prioritize patient care in children with CHC. These efforts include promoting telemedicine in the outpatient setting, using local laboratory testing for follow-up visits, and engaging in the home delivery of DAAs for patients under antiviral therapy whenever possible.

show abstract

Hepatitis C virus infection in children in the era of direct-acting antiviral

Cited by 18 publications

References 95 publications

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

Burden of viral hepatitis caused by specific aetiologies in China, 1990-2016: findings from the GBD 2016

Management of hepatitis C in children and adolescents during COVID-19 pandemic

Contact Info

Product

Resources

About